VERACYTE, INC.

Listed Company

VCYTCIK 0001384101NasdaqLarge AcceleratedServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$517.14M

Net Income

$66.35M

Total Assets

$1.41B

Equity

$1.31B

Shares Out

79.79M

Op. Cash Flow

$136.31M

VCYT$58.31+140.85% · past yearDBEQ Basic

Daily closing prices

Business

Veracyte is a global diagnostics company that develops and commercializes molecular diagnostic tests to guide cancer care decisions. The company offers laboratory-developed tests (LDTs) in the U.S. through CLIA-certified labs for prostate, thyroid, bladder, and breast cancers, and distributes in vitro diagnostic (IVD) tests internationally through laboratories and hospitals. Veracyte serves patients across the cancer care continuum using whole-transcriptome and whole-genome analysis, with revenue primarily from Decipher Prostate and Afirma tests, and growth drivers including the MRD platform TrueMRD and expanded global IVD distribution.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	517	446	361	297	220
Intangible asset amortization - cost of revenue	11	12	18	19	—
Total cost of revenue	155	148	131	121	—
Gross profit	363	298	230	176	—
Research and development	71	69	57	41	30
Selling and marketing	100	95	101	98	80
General and administrative	111	111	86	73	101
Impairment of assets	21	3	68	3	0
Total operating expenses	305	282	315	217	301
Income (loss) from operations	58	16	−86	−41	−82
Other income, net	10	10	9	5	254,000
Income (loss) before income taxes	68	26	−77	−36	−82
Income tax provision (benefit)	2	2	−2	100,000	−6
Net income (loss)	66	24	−74	−37	−76
Basic (in USD per share)	0.84	0.32	−1.02	−0.51	−1.11
Diluted (in USD per share)	0.82	0.31	−1.02	−0.51	−1.11
Basic (in shares)	79	76	73	72	68
Diluted (in shares)	81	78	73	72	68

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	363	239	216	154	173
Short-term investments	50	50	0	25	—
Accounts receivable	45	47	40	44	41
Supplies and inventory	21	22	16	14	11
Prepaid expenses and other current assets	10	15	13	11	13
Total current assets	488	372	286	249	243
Property, plant and equipment, net	22	23	21	18	15
Right-of-use assets, operating leases	37	48	10	13	16
Intangible assets, net	89	102	89	175	203
Goodwill	767	746	703	696	708
Restricted cash	2	2	—	—	—
Other assets	902,000	7	6	5	2
Total assets	1,406	1,300	1,115	1,156	1,188
Accounts payable	5	9	13	12	12
Accrued liabilities	49	44	38	38	39
Current portion of deferred revenue	1	2	2	3	5
Current portion of acquisition-related contingent consideration	1	17	3	6	3
Current portion of operating lease liabilities	4	8	5	4	4
Current portion of other liabilities	0	19,000	101,000	186,000	231,000
Total current liabilities	60	79	61	63	64
Deferred tax liability	646,000	1	734,000	5	6
Acquisition-related contingent consideration, net of current portion	257,000	561,000	518,000	2	6
Operating lease liabilities, net of current portion	36	43	8	11	14
Other liabilities	0	411,000	786,000	931,000	1
Total liabilities	96	124	71	81	91
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized, 79,359,005 and 77,772,678 shares issued and outstanding as of December 31, 2025 and 2024, respectively	79,000	78,000	73,000	72,000	71,000
Additional paid-in capital	1,695	1,656	1,536	1,500	1,469
Accumulated deficit	−378	−444	−468	−394	−357
Accumulated other comprehensive loss	−8	−36	−24	−31	−15
Total stockholders' equity	1,310	1,176	1,044	1,075	1,097
Total liabilities and stockholders' equity	1,406	1,300	1,115	1,156	1,188

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	21	23	27	26	20
Loss on disposal of property, plant and equipment	15,000	202,000	271,000	206,000	0
Stock-based compensation	44	36	33	27	23
Deferred income taxes	−581,000	−233,000	−4	133,000	−6
Non-cash lease expense	3	5	4	3	2
Revaluation of acquisition-related contingent consideration	−15	2	−5	154,000	810,000
Amortization of discount on short-term investments	−3	−354,000	−468,000	—	—
Non-cash loss on deconsolidation of subsidiary	7	0	0	—	—
Effect of foreign currency on operations	−4	2	−1	522,000	1
Accounts receivable	−708,000	−6	4	−4	−9
Supplies and inventory	−3	−6	−2	−3	−1
Prepaid expenses and other current assets	−2	−1	−458,000	1	−3
Other assets	525,000	−1	−290,000	−3	−216,000
Operating lease liability	−2	−5	−4	−3	−2
Accounts payable	−1	−4	−134,000	152,000	5
Accrued liabilities and deferred revenue	6	4	−676,000	−4	14
Net cash provided by operating activities	136	75	44	8	−32
Purchase of short-term investments	−150	−50	−20	−34	0
Proceeds from sale of short-term investments	0	0	40	0	0
Proceeds from maturity of short-term investments	153	0	5	13	0
Loss on deconsolidation of subsidiary - cash	−3	0	0	—	—
Acquisition of C2i, net of cash acquired	0	5	0	0	−574
Purchases of property, plant and equipment	−10	−11	−10	−9	−5
Net cash (used in) provided by investing activities	−9	−56	15	−29	−739
Payment of contingent consideration for acquisition	0	−5	0	0	—
Payment of taxes on vested restricted stock units	−18	−11	−7	−3	−9
Proceeds from the exercise of common stock options and employee stock purchases	14	20	10	8	12
Net cash (used in) provided by financing activities	−4	5	3	3	596
Increase in cash, cash equivalents and restricted cash	123	24	62	−18	−175
Effect of foreign currency on cash, cash equivalents and restricted cash	719,000	−424,000	163,000	−592,000	−2
Net increase in cash, cash equivalents and restricted cash	124	23	62	−19	−176
Purchases of property and equipment included in accounts payable and accrued liabilities	2	1	966,000	0	392,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is VERACYTE, INC.'s CIK number?

VERACYTE, INC.'s SEC CIK number is 0001384101 (1384101). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find VERACYTE, INC.'s SEC filings?

All of VERACYTE, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did VERACYTE, INC. last report earnings?

VERACYTE, INC. (VCYT) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001384101-26-000029). This is VERACYTE, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is VERACYTE, INC.'s most recent earnings 8-K?

VERACYTE, INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001384101-26-000029. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View VERACYTE, INC.'s latest earnings 8-K →
Look up any company's CIK number →